[1]
|
Islami, F., Ward, E.M., Sung, H., et al. (2021) Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. JNCI: Journal of the National Cancer Institute, 113, 1648-1669. https://doi.org/10.1093/jnci/djab131
|
[2]
|
Yarchoan, M., Hopkins, A. and Jaffee, E.M. (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. The New England Journal of Medicine, 377, 2500-2501. https://doi.org/10.1056/NEJMc1713444
|
[3]
|
Klempner, S.J., Fabrizio, D., Bane, S., et al. (2020) Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. The Oncologist, 25, e147-e159.
https://doi.org/10.1634/theoncologist.2019-0244
|
[4]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[5]
|
Van Den Bulk, J., Verdegaal, E.M. and De Miranda, N.F. (2018) Cancer Immunotherapy: Broadening the Scope of Targetable Tumours. Open Biology, 8, Article ID: 180037. https://doi.org/10.1098/rsob.180037
|
[6]
|
Merino, D.M., McShane, L.M., Fabrizio, D., et al. (2020) TMB Harmonization Consortium. Establishing Guidelines to Harmonize Tumor Mutational Burden (TMB): In Silico Assessment of Variation in TMB Quantification across Diagnostic Platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project. Journal for ImmunoTherapy of Cancer, 8, e000147. https://doi.org/10.1136/jitc-2019-000147
|
[7]
|
Snyder, A., Makarov, V., Merghoub, T., et al. (2014) Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. The New England Journal of Medicine, 371, 2189-2199. https://doi.org/10.1056/NEJMoa1406498
|
[8]
|
Ang, C., Klempner, S.J., Ali, S.M., et al. (2019) Prevalence of Established and Emerging Biomarkers of Immune Checkpoint Inhibitor Response in Advanced Hepatocellular Carcinoma. Oncotarget, 10, 4018-4025.
https://doi.org/10.18632/oncotarget.26998
|
[9]
|
Li, L., Rao, X., Wen, Z., et al. (2020) Implications of Driver Genes Associated with a High Tumor Mutation Burden Identified Using Next-Generation Sequencing on Immunotherapy in Hepatocellular Carcinoma. Oncology Letters, 19, 2739-2748. https://doi.org/10.3892/ol.2020.11372
|
[10]
|
Mauriello, A., Zeuli, R., Cavalluzzo, B., et al. (2019) High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients Not Undergoing Immunotherapy. Cancers, 11, Article No. 1824. https://doi.org/10.3390/cancers11121824
|
[11]
|
Wang, X. and Li, M. (2019) Correlate Tumor Mutation Burden with Immune Signatures in Human Cancers. BMC Immunology, 20, Article No. 4. https://doi.org/10.1186/s12865-018-0285-5
|
[12]
|
Wang, S., Shi, H.S., Liu, T., et al. (2021) Mutation Profile and Its Correlation with Clinicopathology in Chinese Hepatocellular Carcinoma Patients. Hepatobiliary Surgery and Nutrition, 10, 172-179.
|
[13]
|
Tang, X., Fan, L., Chen, G., Guo, W., Qiu, F., Wang, J., et al. (2018) Higher Level of Tumor Mutational Burden and 11q13 Amplification in Chinese Hepatocellular Carcinoma Patients. Cancer Research, 78, 4349.
https://doi.org/10.1158/1538-7445.AM2018-4349
|
[14]
|
Wong, C.N., Fessas, P., Dominy, K., et al. (2021) Qualification of Tumour Mutational Burden by Targeted Next-Generation Sequencing as a Biomarker in Hepatocellular Carcinoma. Liver International, 41, 192-203.
|
[15]
|
Zhou, W., Fang, D., He, Y. and Wei, J. (2021) Correlation Analysis of Tumor Mutation Burden of Hepatocellular Carcinoma Based on Data Mining. Journal of Gastrointestinal Oncology, 12, 1117-1131.
|
[16]
|
Liu, S., Tang, Q., Huang, J., Zhan, M., Zhao, W., Yang, X., Li, Y., Qiu, L., Zhang, F., Lu, L. and He, X. (2021) Prognostic Analysis of Tumor Mutation Burden and Immune Infiltration in Hepatocellular Carcinoma Based on TCGA Data. Aging, 13, 11257-11280. https://doi.org/10.18632/aging.202811
|
[17]
|
Xie, C., Wu, H.W., Pan, T., et al. (2021) A Novel Panel Based on Immune Infiltration and Tumor Mutational Burden for Prognostic Prediction in Hepatocellular Carcinoma. Aging, 13, 8563-8587. https://doi.org/10.18632/aging.202670
|
[18]
|
Xu, Q.H., Xu, H., Deng, R.S., et al. (2021) Multi-Omics Analysis Reveals Prognostic Value of Tumor Mutation Burden in Hepatocellular Carcinoma. Cancer Cell Internatinal, 21, Article No. 342.
https://doi.org/10.1186/s12935-021-02049-w
|
[19]
|
Dhanasekaran, R., Nault, J.C., Roberts, L.R., et al. (2019) Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 156, 492-509. https://doi.org/10.1053/j.gastro.2018.11.001
|
[20]
|
Zhu, A.X., Finn, R.S., Edeline, J., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Nonrandomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. https://doi.org/10.1016/S1470-2045(18)30351-6
|
[21]
|
Cheng, A.L., Hsu, C., Chan, S.L., et al. (2020) Challenges of Combination Therapy with Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Journal of Hepatology, 72, 307-319. https://doi.org/10.1016/j.jhep.2019.09.025
|
[22]
|
Yang, H.Y., Sun, L.J., Guan, A., et al. (2021) Unique TP53 Neoantigen and the Immune Microenvironment in Long-Term Survivors of Hepatocellular Carcinoma. Cancer Immunology, Immunotherapy, 70, 667-677.
https://doi.org/10.1007/s00262-020-02711-8
|
[23]
|
Xu, J., Zhang, Y., Jia, R., et al. (2019) Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study. Clinical Cancer Research, 25, 515-523. https://doi.org/10.1158/1078-0432.CCR-18-2484
|
[24]
|
Chan, T.A., Yarchoan, M., Jaffee, E., et al. (2019) Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology, 30, 44-56. https://doi.org/10.1093/annonc/mdy495
|
[25]
|
Cai, H., Zhang, Y., Zhang, H., Cui, C., Li, C. and Lu, S. (2020) Prognostic Role of Tumor Mutation Burden in Hepatocellular Carcinoma after Radical Hepatectomy. Journal of Surgical Oncology, 121, 1007-1014.
https://doi.org/10.1002/jso.25859
|
[26]
|
Shrestha, R., Prithviraj, P., Anaka, M., et al. (2018) Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Frontiers in Oncology, 8, Article No. 269.
https://doi.org/10.3389/fonc.2018.00269
|
[27]
|
Yin, L., Zhou, L.Z. and Xu, R.J. (2020) Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Frontiers in Molecular Biosciences, 7, Article ID: 599142.
https://doi.org/10.3389/fmolb.2020.599142
|
[28]
|
Fernandez, E.M., Eng, K., Beg, S., et al. (2019) Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-Based Tumor Mutational Burden Distribution. JCO Precision Oncology, 3, 1-12.
https://doi.org/10.1200/PO.18.00400
|